Aelix Therapeutics will use the $12.7m of funding to advance its HIV vaccine candidate through phase 2 clinical trials.
Aelix Therapeutics, a Spain-based developer of immunotherapies to prevent HIV infection, closed an €11.5m ($12.7m) series A round featuring healthcare group Johnson & Johnson.
The firm, which invested through its Johnson & Johnson Innovation – JJDC subsidiary, was joined by investment fund Ysios Capital, which led the round, and Caixa Capital Risc, financial services firm La Caixa’s venture capital division.
Aelix will use the funding to advance its HTI immunogen HIV vaccine through a phase 2 proof-of-concept efficacy trial in…
